This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
by Zacks Equity Research
ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.
GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
by Zacks Equity Research
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
EXELNegative Net Change FOLDPositive Net Change AMRNPositive Net Change KRYSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
by Zacks Equity Research
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
VRTXPositive Net Change FOLDPositive Net Change CRSPPositive Net Change AVIRPositive Net Change
biotechs earnings
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
by Zacks Equity Research
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.
NVSPositive Net Change VRTXPositive Net Change EDITPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs earnings-preview medical messenger-rna pharmaceuticals vaccines
Gilead Science to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.
GILDNegative Net Change SRPTPositive Net Change IONSPositive Net Change LEGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
by Zacks Equity Research
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
NVSPositive Net Change BAYRYPositive Net Change ZTSPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
VRTXPositive Net Change ARCTPositive Net Change ACADPositive Net Change CRSPPositive Net Change
biotechs
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.
SNYPositive Net Change FOLDPositive Net Change AMRNPositive Net Change KYMRPositive Net Change
biotechnology biotechs earnings pharmaceuticals
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
by Zacks Equity Research
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.
RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change FOLDPositive Net Change
biotechs
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
NVSPositive Net Change BAYRYPositive Net Change MDGLNegative Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
FOLDPositive Net Change INSMPositive Net Change CSTLPositive Net Change
biotechs earnings medical pharmaceuticals
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
by Zacks Equity Research
MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.
AZNPositive Net Change MRKPositive Net Change CSTLPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
by Zacks Equity Research
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
BMYPositive Net Change PFEPositive Net Change FOLDPositive Net Change AMRNPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
by Zacks Equity Research
AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock falls.
FOLDPositive Net Change AMRNPositive Net Change ARDXPositive Net Change ATNMPositive Net Change
biotechs earnings
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
by Zacks Equity Research
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
REGNPositive Net Change SNYPositive Net Change NVSPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
by Zacks Equity Research
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
NVSPositive Net Change BAYRYPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.
MRKPositive Net Change SMMTPositive Net Change CSTLPositive Net Change
biotechs earnings medical pharmaceuticals
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
by Zacks Equity Research
AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.
AZNPositive Net Change NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
by Zacks Equity Research
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
by Zacks Equity Research
BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
BIIBPositive Net Change RHHBYPositive Net Change ANIPNegative Net Change
biotechs earnings medical pharmaceuticals
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
by Zacks Equity Research
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
biotechnology biotechs earnings medical